ABSTRACT BACKGROUND: Community-acquired pneumonia is the most common infectious cause of death in the US. Over the last 2 decades, patient characteristics and clinical care have changed. To understand the impact of these changes, we quantified incidence and mortality trends among elderly adults.
Community-acquired pneumonia is the most common infectious cause of death in the US. Despite the development of a prediction rule to identify low-risk patients who may safely be treated as outpatients, 1 hospitalization rates have increased in both the US and England. 2, 3 Some of this increase is attributable to demographic changes and an increase in comorbid illnesses. 2, 3 Improved survivorship among patients with acute and chronic diseases, especially cardiac disease, may be a driving factor. 4 In addition to impacting incidence, comorbid illnesses, such as diabetes mellitus, are associated with a poor prognosis in pneumonia patients. 5 Clinicians, health services researchers, and the health care quality community have been engaged in a concerted effort to improve the care of pneumonia patients. 6 The National Hospital Quality Measures established by the Centers for Medicare & Medicaid Services and the Joint Commission have encouraged hospitals to meet performance goals. These goals are focused on process measures that include patient testing (oxygenation assessment and obtaining blood cultures) and treatment (timing and choice of antibiotics), as well as preventive interventions (pneumo-coccal vaccination [PV] and influenza vaccination [IV] ). These interventions have been shown, either individually or in combination, to improve the outcomes of communityacquired pneumonia patients. [7] [8] [9] [10] [11] [12] The implementation of clinical pathways also has been shown to improve outcomes. 13 In addition to encouraging the above interventions, pathways guide other clinical decisions, such as the timing of discharge and the switch to oral antibiotics.
The aggregate impact of these epidemiologic and clinical trends on the survival of pneumonia patients is of great importance to clinicians and policymakers, but has not been studied. As physicians are asked to meet performance measures, it is essential for them to understand their impact on outcomes. As health care costs increase, it also is important to examine mortality trends as a measure of the health benefits of increased resource allocation. Our objective was to quantify 30-day mortality trends in elderly Medicare patients diagnosed with community-acquired pneumonia.
METHODS

Data Source and Study Subjects
Our analyses used all claims (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) for a random 20% sample of Medicare patients aged Ն65 years from the Centers for Medicare & Medicaid Services Research Identifiable Files. Cases of community-acquired pneumonia were identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) 14 code combinations as either: a principal diagnosis of pneumonia (codes 481-487) or a principal diagnosis of respiratory distress (code 786) or respiratory failure (code 518), with pneumonia as a secondary diagnosis. These code combinations have been shown to have a diagnostic sensitivity and specificity of 84% and 86%, respectively. 15 Medicare denominator files were used to establish enrollees' demographic characteristics and vital status.
The date of pneumonia diagnosis was defined as the day of admission for inpatients and the first date of an administrative pneumonia claim for outpatients. Outpatient claims or hospital admissions within 30 days of an initial outpatient pneumonia diagnosis or within 30 days after discharge from a hospital admission for pneumonia were not considered new community-acquired pneumonia episodes. Thirty-day mortality was defined as death within 30 days subsequent to the date of diagnosis. This study was approved by the Partners Human Research Committee. 17 Diagnostic codes were included if they appeared at least once during the year before the pneumonia diagnosis. Including this look back, the patient sample is based on 19 years of data. To assess for validity of the coding, 29 univariate logistic regressions were performed, regressing mortality on a single comorbidity. Four of the comorbidity variables predicted a lower mortality risk. This likely reflects a tendency toward coding these conditions in patients without more significant comorbidities. 18 Hypertension, hypothyroidism, obesity, and depression were therefore excluded from subsequent multivariate analyses.
Outcomes and Statistical Analysis
Patient characteristics, site of care, and mortality rates over time were compared using the Mantel-Haenszel chi-square test for trend. For comparative purposes, summary statistics were calculated for the periods 1987-1989 and 2003-2005 , based on the combined samples of the 3 years that comprise each period. Age-and sex-adjusted mortality rates were then calculated based on their distribution in the year 2000.
To examine outcomes, 3 logistic regressions were performed with 30-day mortality as the dependent variable. We used the following independent variables: binary categorical variables for each year (1987 as the referent), age by 5-year category interacted with sex, and 25 comorbidity variables. The regression was first performed on the entire sample of community-acquired pneumonia patients. Second, we estimated the model on the subset of patients with no comorbidities, to isolate changes due solely to the care of pneumonia, independent of any effect due to treatment of comorbid conditions. Third, we repeated the analysis in patients with complicated diabetes mellitus to estimate
CLINICAL SIGNIFICANCE
• The incidence of community-acquired pneumonia has increased, while the proportion of patients aged Ն80 years has increased, as has the frequency of comorbidities.
• Among elderly pneumonia patients, we demonstrate a markedly reduced 30-day mortality over 2 decades that is particularly evident after adjustment for comorbidities.
• Vaccinations and guideline-concordant antibiotics have been shown to reduce mortality. Their greatly increased use rates may explain a large portion of the mortality trend.
the effect of treatment of a major comorbidity on the mortality trends. For each of the 3 regressions, the primary result was the odds ratio (OR) of death in each year relative to 1987. There have been several factors increasing the coding of comorbidities over time: a true increase in frequency; a change in diagnostic criteria over time (for example, diabetes mellitus); and an increase in the number of diagnostic fields available in the claims data. To assess the impact of these changes on the results of the logistic regression, we performed an additional regression on the total sample, restricting patients in all years to a maximum of 5 diagnoses.
All statistical analyses were performed using Statistical Analysis Software, version 9.1.3 (SAS Institute Inc., Cary, NC).
RESULTS
Characteristics of the Study Subjects and Incidence Trends
The total sample of 2,654,955 community-acquired pneumonia subjects included 1,130,919 outpatients and 1,524,036 inpatients. The Table shows the characteristics of the study subjects for the periods 1987-1989 and 2003-2005 . From the early period to the recent period, the proportion of patients aged Ն80 years increased from 42.5% to 47.5% (P Ͻ.001), while the proportion of subjects treated as inpatients decreased from 62.6% to 55.7% (P Ͻ.001). Most of this shift in site of care had occurred by 1998. Mortality summary statistics show a decrease in the total sample, as well as a corresponding decrease within each age group. Figure 1 exhibits the annual incidence of pneumonia for the combined sample as well as for men and women separately. Each trend is adjusted for age (and sex for the combined line). The incidence among both sexes and for the combined sample increased through 1999, declining somewhat thereafter. Figure 2 demonstrates the trend in several common comorbidities. Chronic lung disease, congestive heart failure, and uncomplicated diabetes mellitus were the most frequent, and each was increasing. The proportion of patients with chronic lung disease and congestive heart failure increased from 27.6% to 46.0% (P Ͻ.001) and from 20.0% to 33.3% (P Ͻ.001), respectively. Figure 3 shows the 30-day mortality trends. Overall mortality fell from 13.5% in 1987 to 9.7% in 2005, a 28.1% relative reduction.
Trends in 30-Day Mortality
The Appendix (available online) shows the logistic regression results for mortality in the total sample of patients. Figure 4 depicts the changes in multivariate-adjusted OR of 30-day mortality over the time period studied. A large proportion of the mortality decrease occurred during the 
DISCUSSION
Our findings reveal a substantial mortality reduction in elderly pneumonia patients from 1987 to 2005, over which 
Figure 2
Trends in the frequency of selected comorbid conditions among inpatients and outpatients diagnosed with community-acquired pneumonia. CHF ϭ congestive heart failure; DM ϭ diabetes mellitus.
time the relative risk of mortality fell by 28%, and, after comorbidity adjustment, 54%. Our data demonstrate a 13.5% mortality rate in 1987 that decreased markedly over the period studied. However, even this initial mortality rate reflects a decrease during the 1980s. A Lancet report studying community-acquired pneumonia patients with a mean age of 51 years in 1980 and 1981 showed an in-hospital mortality rate of 15%. 19 Especially given the relatively young age of their subjects, this suggests important improvements were already occurring during the 1980s. Similarly, a prospective study conducted from 1981 to 1987 showed a mortality rate of 28.6% in patients over age 60 years admitted for pneumonia. 20 Our data suggest that mortality due to pneumonia has indeed decreased. We believe that inclusion of outpatients is a strength of our study. Especially as patient care shifts to the outpatient setting, it is crucial for evidence to incorporate these patients. It is important to explain the reduction in mortality. Although our data do not allow us to know with certainty why mortality has decreased, we review the evidence for the likely possibilities. A good part of the improvement may be due to an increase in the use of PV and IV, as well as guideline-concordant antibiotics. Two large studies have shown that PV does little to prevent pneumonia, but markedly reduces the risk of bacteremia and invasive pneumococcal disease, both of which greatly increase mortality risk. 21, 22 One of these studies demonstrated a multivariableadjusted hazard ratio of death due to pneumonia of 0.41 in patients who received PV. 22 Among 17,393 hospitalized community-acquired pneumonia patients, receipt of IV was associated with a 39% lower mortality, after adjusting for receipt of PV. 23 Use of the 23-valent pneumococcal polysaccharide vaccine, which replaced the 14-valent vaccine in 1983, increased sharply after the vaccination recommendations of the Centers for Disease Control and Prevention were published in the Morbidity and Mortality Weekly Report in 1989. [24] [25] [26] From 1989 to 1993, distribution of PV tripled, while distribution of IV doubled. 27 According to the United States Immunization Survey, 10.7% and 23.0% of elderly adults in 1985 had received PV and IV, respectively. In 1989, the National Health Interview Survey showed that 14.7% and 32.9% of elderly adults received PV and IV, respectively. We use the means of these rates to establish estimated reference year 1987 PV and IV rates of 12.7% and 28.0%, respectively. More recently, the Behavioral Risk Factor Surveillance System estimated that, in 2005, 65.7% and 65.5% of elderly adults received PV and IV, respectively. There is little controversy about the mortality benefit of IV in pneumonia. However, we recognize that there is varied opinion about the benefit of PV. Although we reference high-quality studies that showed a mortality benefit of PV, a Cochrane Review did conclude that the evidence for a mortality benefit was not compelling. 28 Recommendations for combination antibiotic therapy were published in 1987, and are part of the 1993 American Thoracic Society guidelines for community-acquired pneumonia management. 29, 30 Such combination, guideline-concordant antibiotics 31 have been shown to achieve large mortality reductions. [7] [8] [9] [32] [33] [34] For example, among community-dwelling hospitalized elderly pneumonia patients, 3 guideline-concordant antibiotic regimens reduced 30-day mortality with hazard ratios of 0.64-0.78, compared with monotherapy. 34 One study based on 1992 data demonstrated that only 54% of pneumonia patients received such antibiotics. 35 More recent data have shown a guideline-concordant antibiotics use rate of 88%. 9 We believe that the exponential increases in influenza, and possibly pneumococcal, vaccination, as well as greater use of guideline-concordant antibiotics explain a sizable portion of the mortality reduction we demonstrate. The referenced studies examined largely inpatients, and therefore must be used cautiously in explaining trends in a combined sample including outpatients. Still, they merit further exploration. Early administration of antibiotics and obtaining blood cultures are probably beneficial, but the literature suggests a less substantial impact. 10 There also is a burgeoning literature on the infection-related mortality reduction associated with statin use. [36] [37] [38] Although causality has not yet been established in controlled trials, 39 the remarkable increase in statin use may be decreasing pneumonia mortality.
Even as mortality from pneumonia fell, the incidence increased from 1987 to 1999. We believe this is largely due to an increase in the frequency of comorbidities that predispose patients to developing pneumonia. The decrease we find after 1999 is consistent with other published data. 2 Although we cannot perfectly explain this reduced incidence, several factors are likely at work: the modest effect of higher PV rates on the risk of pneumonia; reductions in smoking; and better treatment of the comorbid conditions that are risk factors for pneumonia. Reduced use of oral and inhaled corticosteroids in patients with chronic lung disease also may be playing a role, 40 as may increased use of statins. 38 Finally the increase in influenza vaccination in recent years and corresponding reduction in risk for bacterial pneumonia is probably decreasing incidence. There are limitations to this investigation. We identified pneumonia patients based on an administrative dataset rather than clinical chart review. It is possible that we excluded cases of community-acquired pneumonia and that some of our patient sample had nosocomial pneumonia. However, our patient identification methods were validated in a study showing a 93% positive predictive value. Moreover, any imperfections in the inclusion process should have been constant over time. For these reasons, we believe the small number of patients incorrectly included or excluded would not appreciably impact our results. Our conclusions also are limited by our inability to explain with confidence the reasons for the mortality decrease.
Also, the increase in frequency of comorbidities over time reflects, to some extent, changes in coding practices and disease definitions rather than a true change in physiologically comparable prevalence. However, many of these diseases have in fact increased in prevalence over time, and 2 recent studies of pneumonia patients also have documented their increasing frequency. 2, 3 Additionally, restricting all patients to 5 diagnoses changed the results only a small amount-not enough to change the overall conclusions or implications of our study. Rather, it supports the primary conclusion that care of pneumonia patients has indeed improved. Our study also is limited by the absence of laboratory data and physiologic variables. We were therefore unable to perform risk adjustment as accurately as the pneumonia severity index would have. However, because age and comorbidities contribute a great deal to the pneu-monia severity index, it is probable that its incorporation would not have a large impact on the identified trends. Some portion of the incidence trend and the substantial reduction in mortality we demonstrate could be due to a change in coding practices. For example, if patients with bronchitis were increasingly likely to be coded as pneumonia, this would explain some of the mortality reduction. Similarly, if patients in recent years with sepsis due to pneumonia were coded with a principal diagnosis of sepsis at a higher rate than in the early years, this might artifactually reduce mortality because our validated diagnostic code algorithm would not capture this trend. Although experienced professional coders at the Massachusetts General Hospital with whom we consulted did not believe such a trend has occurred, we think it important to recognize this as a potential influence on mortality trends examined using administrative data.
In summary, we found significant improvements in survival among a large sample of community-acquired pneumonia patients from 1987 to 2005. The few other studies of mortality trends in pneumonia 2, 42 have had limitations, which our study addresses. This is the first study to use 2 decades of data to examine 30-day, adjusted mortality trends, including comorbid conditions, in a combined sample of noninstitutionalized inpatients and outpatients. Improved survival is consistent with data showing increased use of guideline-concordant combination antibiotic therapy, as well as vaccination, which may collectively explain a large proportion of the mortality decrease we found. Additional efforts to get all providers to use these measures might reduce mortality from pneumonia even further.
